Mini Review ARTICLE
Functional muscle ischemia in Duchenne and Becker muscular dystrophy
- Heart and Vascular Institute, Penn State College of Medicine, Hershey, PA, USA
Duchenne and Becker muscular dystrophy (DMD/BMD) comprise a spectrum of devastating X-linked muscle wasting disease for which there is no treatment. DMD/BMD is caused by mutations in the gene encoding dystrophin, a cytoskeletal protein that stabilizes the muscle membrane and also targets other proteins to the sarcolemma. Among these is the muscle-specific isoform of neuronal nitric oxide synthase (nNOSμ) which binds spectrin-like repeats within dystrophin's rod domain and the adaptor protein α-syntrophin. Dystrophin deficiency causes loss of sarcolemmal nNOSμ and reduces paracrine signaling of muscle-derived nitric oxide (NO) to the microvasculature, which renders the diseased muscle fibers susceptible to functional muscle ischemia during exercise. Repeated bouts of functional ischemia superimposed on muscle fibers already weakened by dystrophin deficiency result in use-dependent focal muscle injury. Genetic and pharmacologic strategies to boost nNOSμ-NO signaling in dystrophic muscle alleviate functional muscle ischemia and show promise as novel therapeutic interventions for the treatment of DMD/BMD.
Duchenne and Becker muscular dystrophy (DMD/BMD) comprise a spectrum of devastating X-linked muscle wasting disease accounting for over 80% of all cases of muscular dystrophy (Bushby et al., 2010a). In DMD, boys are diagnosed as toddlers and most are wheelchair bound by age 15. Death often occurs by age 20 from respiratory complications or cardiomyopathy. More patients survive to age 30 due to home ventilation and corticosteroids, which can prolong ambulation by 2–3 years, reduce risk of scoliosis, and mitigate pulmonary and cardiac decline in the second decade (Bushby et al., 2010a,b). Despite this demonstrated efficacy, more than 25% of boys with DMD are not treated with corticosteroids due to intolerable side-effects or lack of response (Bushby et al., 2010a,b). In BMD, the disease is milder and more clinically heterogenous than DMD. Muscle weakness often is first noticed in adolescence or young adulthood. Cardiac decline in BMD patients may surpass skeletal muscle decline, with death from cardiomyopathy often occurring before age 60 (Bushby et al., 2010a). There is a clear need for additional therapeutic strategies to manage the clinical challenges of DMD/BMD.
More than 25 years have passed since mutations in the DMD gene were discovered to cause DMD/BMD (Monaco et al., 1986; Koenig et al., 1987). Mutations resulting in the absence of a functional dystrophin protein cause DMD, whereas mutations resulting in a reduced amount or shortened dystrophin protein cause BMD. Dystrophin is a large (427 kDa) sub-sarcolemmal protein that provides a physical link between the intracellular actin cytoskeleton and the extracellular matrix (Blake et al., 2002). Loss of dystrophin destabilizes the sarcolemma, rendering the muscle fibers susceptible to injury during contraction (Petrof et al., 1993). Repeated cycles of necrosis followed by regeneration lead to satellite cell depletion and gradual replacement of muscle by fat and connective tissue, manifesting clinically as progressive muscle wasting and weakness (Blake et al., 2002). Dystrophin also is a scaffolding protein that localizes other structural and signaling proteins to the sarcolemma, forming a highly organized multimeric dystrophin-associated glycoprotein complex (DGC) (Blake et al., 2002). Dystrophin deficiency disrupts the DGC, resulting in the absence, downregulation, or mislocalization of the dystrophin-associated proteins. Thus, numerous pathogenetic mechanisms are likely activated in dystrophin-deficient muscle in response to disruption of the sarcolemmal DGC. Identifying the key mechanistic link(s) between loss of dystrophin and the clinical phenotype of DMD/BMD has been a major focus of research efforts with the ultimate goal of discovering new therapeutic targets to slow or prevent the dystrophic process.
The Vascular Hypothesis of DMD
One putative mechanism that has received increased attention recently is muscle ischemia. One of the earliest histological changes seen in dystrophic muscle, even before the onset of significant muscle weakness, is the appearance of small random groups of muscle fibers at the same stage of necrosis or regeneration surrounded by histologically normal muscle fibers (Engel, 1967). In the pre-dystrophin era, it was proposed that this characteristic focal necrosis might reflect local microvascular ischemia. The idea was that vascular insufficiency at the level of the microcirculation caused selective infarction of only those muscle fibers supplied by the obstructed blood vessels, while nearby fibers supplied by unobstructed vessels were not affected (Bramwell, 1925; Demos and Escoiffier, 1957; Cazzato, 1968). Initial experimental support for this vascular hypothesis came from studies performed more than 40 years ago in which the characteristic focal lesions of DMD muscle were reproduced in the muscles of healthy animals by occlusion of intramuscular arterioles with dextran beads, or by functional ischemia induced by a combination of arterial ligation and vasoconstrictor injection (Hathaway et al., 1970; Mendell et al., 1971, 1972). However, subsequent morphological studies did not reveal any fixed anatomical abnormalities in the skeletal muscle microcirculation of DMD patients, with the exception of replication of the capillary basal lamina (Jerusalem et al., 1974; Musch et al., 1975; Koehler, 1977; Leinonen et al., 1979). In addition, findings from studies of skeletal muscle blood flow in DMD patients were equivocal, indicating that blood flow to resting muscle was decreased, increased, or normal (Demos, 1961; Emery and Schelling, 1965; Kapuscinska et al., 1970; Paulson et al., 1974; Bradley et al., 1975; Leinonen et al., 1979). The lack of any identifiable cause of muscle ischemia in DMD patients diminished enthusiasm for the vascular hypothesis.
Functional Muscle Ischemia Due to Loss of Sarcolemmal nNOSμ
It was not until after the discovery of dystrophin and the DGC that the vascular hypothesis re-emerged. Among the dystrophin-associated proteins is neuronal nitric oxide synthase μ (nNOSμ), a muscle-specific splice variant of NOS, which is recruited to the sarcolemma by two independent interactions involving its PDZ (post-synaptic density 95, discs large, and zonula occludens-1) domain. The nNOSμ PDZ β-finger interacts with the PDZ domain of the adaptor protein α-syntrophin, which binds to dystrophin's C-terminal domain, while the nNOSμ PDZ groove interacts with spectrin-like repeats 16 and 17 (R16/17) within dystrophin's rod domain (Brenman et al., 1995; Chang et al., 1996; Lai et al., 2009, 2013). Dystrophin deficiency causes nNOSμ to be misplaced from the sarcolemma to the cytosol where the residual amount of protein is also greatly reduced (Brenman et al., 1995; Chang et al., 1996; Chao et al., 1996; Torelli et al., 2004; Kobayashi et al., 2008). Parallel translational experiments in mouse models and boys with DMD showed that loss of sarcolemmal nNOSμ renders the dystrophin-deficient muscle fibers susceptible to muscle ischemia during exercise (Thomas et al., 1998, 2003; Sander et al., 2000; Lai et al., 2009). As shown in Figure 1, NO produced by sarcolemmal nNOSμ normally acts as a local paracrine signal that optimizes blood flow in the working muscles by attenuating sympathetic (i.e., α-adrenergic) vasoconstriction (Thomas and Victor, 1998; Thomas et al., 1998, 2003; Sander et al., 2000; Chavoshan et al., 2002). This protective mechanism, termed functional sympatholysis, is impaired in the mdx mouse model of DMD, in boys with DMD, and in men with BMD, resulting in functional muscle ischemia due to unopposed sympathetic vasoconstriction (Thomas et al., 1998; Sander et al., 2000; Martin et al., 2012). A similar impairment is present in the contracting muscles of nNOS null mice, indicating that the defective vasoregulation in dystrophin-deficient muscle is likely due to the loss of sarcolemmal nNOSμ (Thomas et al., 1998). This is further substantiated by proof-of-concept experiments in α-syntrophin null mice and in transgenic mice expressing a mutated α-syntrophin lacking its PDZ domain, both of which are characterized by a selective reduction of sarcolemmal, but not cytosolic, nNOSμ (Kameya et al., 1999; Adams et al., 2001; Thomas et al., 2003). These mice also display an impaired NO-dependent modulation of α-adrenergic vasoconstriction in contracting skeletal muscle, a defect that is corrected by the reestablishment of normal levels of sarcolemmal nNOSμ in transgenic mice expressing full-length α-syntrophin (Thomas et al., 2003). Furthermore, in mdx mice functional muscle ischemia is alleviated and exercise tolerance is improved by expression of a R16/17-containing synthetic dystrophin minigene that restores sarcolemmal nNOSμ (Lai et al., 2009; Zhang et al., 2013). In contrast, muscle ischemia persists in mdx mice expressing a R16/17-lacking dystrophin minigene that restores all of the DGC except nNOSμ (Lai et al., 2009).
Figure 1. Left panel, in healthy muscle, nNOSμ is localized to the sarcolemma by association with the rod domain of dystrophin and the PDZ domain of α-syntrophin (syn). During muscle contraction, some of the nNOSμ-derived nitric oxide (NO) diffuses to the nearby microvessels where it increases cGMP and attenuates norepinephrine (NE)-mediated vasoconstriction. This NO-mediated functional sympatholysis optimizes blood flow in the working muscles. Right panel, in dystrophic muscle, nNOSμ is reduced in amount and mislocalized from the sarcolemma to the cytosol. Less NO is generated during muscle contraction, resulting in unrestrained sympathetic vasoconstriction and transient functional muscle ischemia, which may exacerbate injury of the diseased muscle fibers. Genetic and pharmacologic interventions targeting different aspects of nNOSμ-NO signaling that alleviate functional muscle ischemia in preclinical studies are shown. sGC, soluble guanylyl cyclase; DG, dystroglycan; PDE, phosphodiesterase.
Collectively, these observations in numerous mouse models and in DMD/BMD patients have advanced the concept that NO produced by sarcolemmal nNOSμ helps to regulate blood flow in active muscle by blunting the potentially deleterious effect of sympathetic activation during exercise. The loss of this protective mechanism may leave dystrophin-deficient skeletal muscle vulnerable to recurrent bouts of ischemia, thereby promoting muscle fatigue and exacerbating use-dependent muscle injury (Rando, 2001; Asai et al., 2007). Consistent with this hypothesis, mdx mice display an exaggerated exercise-induced fatigue response that is associated with reduced muscle perfusion and increased focal constriction of muscle microvessels (Kobayashi et al., 2008). The exaggerated fatigue response in the mdx mice appears to be due to the loss of sarcolemmal nNOSμ, as excessive fatigue also is observed in nNOS null mice and in wild type mice treated with a nNOS-specific inhibitor (Kobayashi et al., 2008). Reduced NO signaling also contributes to contraction-induced injury of dystrophin-deficient muscle. Mdx muscle exhibits progressive damage post-contraction that can be alleviated by treatment with a NO donor (Asai et al., 2007). Thus, the updated version of the vascular hypothesis of DMD suggests that the nNOSμ-NO pathway could be considered as a potential new drug target to slow disease progression in DMD/BMD patients.
However, many questions remain about the nature of the ischemic stimulus and the long term effects of ischemia on dystrophic muscle. For example, vasoconstrictor responses to activation of sympathetic nerves are reduced in the resting cremaster muscles of mdx mice (Bagher et al., 2011), suggesting that there may be less sympathetic vasoconstriction to oppose during exercise. While this does not appear to be the case in the forearm muscles of DMD/BMD patients (Sander et al., 2000; Martin et al., 2012), studies of other muscles including locomotor muscles are warranted. Whether other metabolic vasodilator pathways independent of nNOSμ-NO (e.g., H+, K+, ATP) are impaired and contribute to functional ischemia has yet to be explored in dystrophic muscle. Also unknown is if functional ischemia manifests primarily as maldistribution of blood flow within the active muscles or as reduced total muscle blood flow. Compensatory mechanisms such as angiogenesis that are engaged to counteract muscle ischemia appear to be robust in young mdx mice (Straino et al., 2004), but impaired in older mdx mice (Palladino et al., 2013), suggesting that the impact of muscle ischemia on disease progression may vary over time.
Restoring nNOSμ-No Signaling to Alleviate Muscle Ischemia
In the absence of dystrophin, nNOSμ is both reduced in content and misplaced from the sarcolemma to the cytosol (Brenman et al., 1995; Chang et al., 1996; Chao et al., 1996; Torelli et al., 2004; Kobayashi et al., 2008). Feasible approaches to improve NO signaling in dystrophic muscle have therefore focused largely on providing exogenous NO, restoring normal levels and sarcolemmal localization of nNOSμ, or enhancing effects of residual cytosolic nNOSμ. Multiple genetic and pharmacologic strategies that boost nNOSμ-NO signaling have been shown to ameliorate many features of the dystrophic phenotype—at least in the mdx mouse. These strategies include genetic overexpression of NOS isoforms in muscle (Wehling et al., 2001; Tidball and Wehling-Henricks, 2004; Wehling-Henricks et al., 2005; Colussi et al., 2008), expression of dystrophin mini-genes that restore sarcolemmal nNOSμ (Lai et al., 2009, 2013), supplementation with the NOS substrate L-arginine to increase endogenous NO production from cytosolic nNOSμ (Barton et al., 2005; Voisin et al., 2005; Archer et al., 2006; Hnia et al., 2008; Guerron et al., 2010), treatment with NO-donating drugs (Marques et al., 2005; Brunelli et al., 2007; Benabdellah et al., 2009; Mizunoya et al., 2011; Sciorati et al., 2011; Thomas et al., 2012), and phosphodiesterase 5A (PDE5A) inhibition to prolong the half-life of cGMP arising from the residual NO generated by cytosolic nNOSμ (Asai et al., 2007; Kobayashi et al., 2008).
There is evidence to suggest that some of the beneficial effects of boosting nNOSμ-NO signaling in dystrophin-deficient muscle are likely due to correction of the abnormal vascular phenotype of functional muscle ischemia. In the mdx mouse, PDE5A inhibitors have been shown to ameliorate muscle ischemia, muscle injury, and muscle fatigue after a brief bout of downhill exercise (Kobayashi et al., 2008). In this seminal study by Kobayashi and colleagues, the effect was dramatic and immediate and was seen with two different PDE5A inhibitors, tadalafil and sildenafil. Acute tadalafil treatment has also been shown to reduce contraction-induced injury in mdx mice, while chronic treatment begun in utero improves muscle morphology, attenuates sarcolemmal damage, and reduces muscle fibrosis (Asai et al., 2007). Chronic sildenafil treatment has been shown to improve cardiac dynamics in mdx mice and to rescue dystrophic skeletal muscle and prolong survival in a zebrafish model of DMD (Khairallah et al., 2008; Adamo et al., 2010; Kawahara et al., 2011).
PDE5A inhibitors have proven to be safe and effective not only for patients with erectile dysfunction but also for those with pulmonary hypertension (Ravipati et al., 2007). Given the encouraging findings of pre-clinical studies in the mdx mouse, Martin and colleagues recently tested the translational potential of PDE5A inhibition to benefit patients with muscular dystrophy (Martin et al., 2012). They showed that treatment with a single dose of tadalafil rescued the abnormal vascular phenotype in the muscle of patients with BMD, fully restoring NO-dependent modulation of reflex sympathetic vasoconstriction in the exercising muscles. Tadalafil alleviated microvascular ischemia and fully restored muscle blood flow regulation in 8 of the 9 BMD patients studied (Martin et al., 2012). This finding is consistent with the hypothesis that PDE5A inhibition boosts a residual NO-cGMP signal arising from nNOSμ misplaced to the cytosol of dystrophin-deficient muscle. It is not clear why one patient did not respond to tadalafil, but conceivably some patients with DMD/BMD might have such a low level of residual muscle nNOSμ that the NO-cGMP signal is insufficient for the PDE5A inhibitor to boost. For such patients, NO-donating drugs could offer an alternative approach to restore NO signaling.
The use of NO-donating drugs in muscular dystrophy was first suggested in 2005 when Voisin and colleagues showed that 6 weeks of daily molsidomine treatment of mdx mice increased muscle utrophin, reduced creatine kinase, and reduced muscle necrosis (Voisin et al., 2005). Despite the beneficial effects observed in this short-term study, molsidomine may not be the best choice for long-term NO replacement in dystrophic muscle because the drug is metabolized to SIN-1 in the liver, which decomposes into NO and superoxide that can combine to form the damaging free radical peroxynitrite (Singh et al., 1999). Over time, this could be detrimental as dystrophin-deficient muscle cells are highly sensitive to free radical injury (Rando, 2002). Furthermore, unlike the PDE5A inhibitors, acute treatment with molsidomine did not reduce exercise-induced fatigue in mdx mice (Kobayashi et al., 2008).
Another class of NO-donating drug that has shown potential in pre-clinical mdx mouse studies is the cyclooxygenase (COX)-inhibiting NO donor (CINOD) that combines a standard COX inhibitor with a NO-donating moiety to produce dual pharmacological action (Keeble and Moore, 2002; Wallace et al., 2009). Chronic treatment (6–12 months) of mdx and α-sarcoglycan null mice with the CINOD HCT 1026, a NO-donating flurbiprofen, has been shown to improve muscle morphology and reduce muscle necrosis, inflammation, and fatigue (Brunelli et al., 2007). Similar effects have been observed in α-sarcoglycan null mice treated with NCX 320, a NO-donating ibuprofen (Sciorati et al., 2011). Improved muscle blood flow may contribute to the beneficial effects of these drugs as short-term treatment for as little as 1 month with HCT 1026 reverses functional muscle ischemia in mdx mice (Thomas et al., 2012). Importantly, the effect of HCT 1026 to prevent functional muscle ischemia does not abate with prolonged treatment, negating the concern that tolerance to the drug might develop with chronic use (Thomas et al., 2012). This is a potential drawback for some commonly used NO donors such as the organic nitrates (e.g., nitroglycerin), which lose vasodilator potency during continuous exposure (Munzel et al., 2005). Translational studies to determine if CINODs ameliorate functional muscle ischemia have yet to be carried out in patients with DMD/BMD. However, an initial 12-month pilot study has shown that co-administration of the NO donor isosorbide dinitrate and COX inhibitor ibuprofen is safe and well-tolerated in adult dystrophic patients (D'Angelo et al., 2012).
While boosting nNOSμ-NO signaling appears to be an effective means to normalize muscle blood flow regulation in the mdx mouse, it is likely to have additional mechanistic influences as well. NO derived from nNOSμ has been shown to regulate force generation, muscle mass, fatigue, muscle repair from injury, oxidative stress, and inflammation (Stamler and Meissner, 2001; Powers and Jackson, 2008). Thus, boosting NO signaling may improve DMD/BMD by a variety of mechanisms that include: (a) improving muscle blood flow and oxygen delivery (Thomas et al., 1998; Sander et al., 2000; Asai et al., 2007; Kobayashi et al., 2008; Martin et al., 2012); (b) decreasing muscle inflammation (Brunelli et al., 2007; Lai et al., 2009; Sciorati et al., 2011); (c) inhibiting histone deacetylase (HDAC) activity (Colussi et al., 2008; Cacchiarelli et al., 2010); (d) reducing muscle fibrosis (Asai et al., 2007; Guerron et al., 2010); (e) enhancing satellite cell activation during muscle repair (Anderson, 2000; Brunelli et al., 2007); (f) upregulating muscle utrophin—a dystrophin homolog with functional similarities (Voisin et al., 2005; Hnia et al., 2008); and (g) ameliorating cardiac dysfunction (Khairallah et al., 2008; Adamo et al., 2010). Although the majority of studies to date have reported favorable effects of boosting NO signaling in dystrophic muscle, further careful analysis of the long-term effects of these strategies is necessary as several studies have shown detrimental effects of mislocalized NO signaling in skeletal muscle. Increased cytosolic nNOSμ is postulated to mediate disuse muscle atrophy in normal mouse muscle by non-hemodynamic mechanisms (e.g., involving Foxo transcription factors) (Suzuki et al., 2007) and to reduce force production in dystrophic mouse muscle by hypernitrosylation of ryanodine receptors (Li et al., 2011).
Recent findings from preclinical studies in the mdx mouse and clinical studies in DMD/BMD patients have led to renewed interest in the vascular hypothesis of muscular dystrophy. The refined hypothesis now provides a molecular mechanism, loss of sarcolemmal nNOSμ and reduced paracrine NO signaling to the muscle microvasculature, to explain the occurrence of functional muscle ischemia in dystrophin-deficient muscle. Strategies to restore nNOSμ-NO signaling in dystrophic muscle that alleviate functional muscle ischemia include dystrophin minigene therapy, PDE5A inhibition, and NO-donating drugs. The initial reports showing largely beneficial effects of restoring NO signaling in dystrophic mouse muscle suggest that reducing muscle ischemia may allow DMD/BMD patients to perform more work with less muscle injury and fatigue, thereby slowing disease progression and improving quality of life.
Conflict of Interest Statement
The author has received funding and research materials from Nicox Research Institute, which is the source of one of the drugs (HCT 1026) discussed in the article.
The author is supported by funding from the NIH (R01-AR056221) and Department of Defense (W81XWH-12-1-0256).
Adamo, C. M., Dai, D. F., Percival, J. M., Minami, E., Willis, M. S., Patrucco, E., et al. (2010). Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 107, 19079–19083. doi: 10.1073/pnas.1013077107
Adams, M. E., Mueller, H. A., and Froehner, S. C. (2001). In vivo requirement of the α-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J. Cell Biol. 155, 113–122. doi: 10.1083/jcb.200106158
Archer, J. D., Vargas, C. C., and Anderson, J. E. (2006). Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 20, 738–740. doi: 10.1096/fj.05-4821fje
Asai, A., Sahani, N., Kaneki, M., Ouchi, Y., Martyn, J. A., and Yasuhara, S. E. (2007). Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS ONE 2:e806. doi: 10.1371/journal.pone.0000806
Bagher, P., Duan, D., and Segal, S. S. (2011). Evidence for impaired neurovascular transmission in a murine model of Duchenne muscular dystrophy. J. Appl. Physiol. 110, 601–609. doi: 10.1152/japplphysiol.01106.2010
Barton, E. R., Morris, L., Kawana, M., Bish, L. T., and Toursel, T. (2005). Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 32, 751–760. doi: 10.1002/mus.20425
Benabdellah, F., Yu, H., Brunelle, A., Laprevote, O., and De La Porte, S. (2009). MALDI reveals membrane lipid profile reversion in MDX mice. Neurobiol. Dis. 36, 252–258. doi: 10.1016/j.nbd.2009.07.013
Blake, D. J., Weir, A., Newey, S. E., and Davies, K. E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291–329. doi: 10.1152/physrev.00028.2001
Bradley, W. G., O'Brien, M. D., Walder, D. N., Murchison, D., Johnson, M., and Newell, D. J. (1975). Failure to confirm a vascular cause of muscular dystrophy. Arch. Neurol. 32, 466–473. doi: 10.1001/archneur.1975.00490490070007
Brenman, J. E., Chao, D. S., Xia, H., Aldape, K., and Bredt, D. S. (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82, 743–752. doi: 10.1016/0092-8674(95)90471-9
Brunelli, S., Sciorati, C., D'Antona, G., Innocenzi, A., Covarello, D., Galvez, B. G., et al. (2007). Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc. Natl. Acad. Sci. U.S.A. 104, 264–269. doi: 10.1073/pnas.0608277104
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., et al. (2010a). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77–93. doi: 10.1016/S1474-4422(09)70271-6
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., et al. (2010b). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9, 177–189. doi: 10.1016/S1474-4422(09)70272-8
Cacchiarelli, D., Martone, J., Girardi, E., Cesana, M., Incitti, T., Morlando, M., et al. (2010). MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 12, 341–351. doi: 10.1016/j.cmet.2010.07.008
Cazzato, G. (1968). Considerations about a possible role played by connective tissue proliferation and vascular disturbances in the pathogenesis of progressive muscular dystrophy. Eur. Neurol. 1, 158–179. doi: 10.1159/000113659
Chang, W. J., Iannaccone, S. T., Lau, K. S., Masters, B. S. S., McCabe, T. J., McMillan, K., et al. (1996). Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 93, 9142–9147. doi: 10.1073/pnas.93.17.9142
Chao, D. S., Gorospe, J. R., Brenman, J. E., Rafael, J. A., Peters, M. F., Froehner, S. C., et al. (1996). Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J. Exp. Med. 184, 609–618. doi: 10.1084/jem.184.2.609
Chavoshan, B., Sander, M., Sybert, T. E., Hansen, J., Victor, R. G., and Thomas, G. D. (2002). Nitric oxide-dependent modulation of sympathetic neural control of oxygenation in exercising human skeletal muscle. J. Physiol. 540, 377–386. doi: 10.1113/jphysiol.2001.013153
Colussi, C., Mozzetta, C., Gurtner, A., Illi, B., Rosati, J., Straino, S., et al. (2008). HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. U.S.A. 105, 19183–19187. doi: 10.1073/pnas.0805514105
D'Angelo, M. G., Gandossini, S., Martinelli Boneschi, F., Sciorati, C., Bonato, S., Brighina, E., et al. (2012). Nitric oxide donor and nonsteroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol. Res. 65, 472–479. doi: 10.1016/j.phrs.2012.01.006
Demos, J. (1961). Mesures des temps de circulation chez 79 myopathes. Etude statistique des resultats. role du degre de l'atteinte musculaire clinique, du mode evolutif de la maladie, du sexe du malade, des saisons. Rev. Fr. Etudes Clin. Biol. 6, 876–887.
Guerron, A. D., Rawat, R., Sali, A., Spurney, C. F., Pistilli, E., Cha, H. J., et al. (2010). Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS ONE 5:e11220. doi: 10.1371/journal.pone.0011220
Hathaway, P. W., Engel, W. K., and Zellweger, H. (1970). Experimental myopathy after microarterial embolization; comparison with childhood x-linked pseudohypertrophic muscular dystrophy. Arch. Neurol. 22, 365–378. doi: 10.1001/archneur.1970.00480220079011
Hnia, K., Gayraud, J., Hugon, G., Ramonatxo, M., De La Porte, S., Matecki, S., et al. (2008). L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 172, 1509–1519. doi: 10.2353/ajpath.2008.071009
Kameya, S., Miyagoe, Y., Nonaka, I., Ikemoto, T., Endo, M., Hanaoka, K., et al. (1999). α1-syntrophin gene disruption results in the absence of neuronal-type nitric oxide synthase at the sarcolemma but does not induce muscle degeneration. J. Biol. Chem. 274, 2193–2200. doi: 10.1074/jbc.274.4.2193
Kawahara, G., Karpf, J. A., Myers, J. A., Alexander, M. S., Guyon, J. R., and Kunkel, L. M. (2011). Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 108, 5331–5336. doi: 10.1073/pnas.1102116108
Keeble, J. E., and Moore, P. K. (2002). Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. 137, 295–310. doi: 10.1038/sj.bjp.0704876
Khairallah, M., Khairallah, R. J., Young, M. E., Allen, B. G., Gillis, M. A., Danialou, G., et al. (2008). Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc. Natl. Acad. Sci. U.S.A. 105, 7028–7033. doi: 10.1073/pnas.0710595105
Kobayashi, Y. M., Rader, E. P., Crawford, R. W., Iyengar, N. K., Thedens, D. R., Faulkner, J. A., et al. (2008). Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456, 511–515. doi: 10.1038/nature07414
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., and Kunkel, L. M. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509–517. doi: 10.1016/0092-8674(87)90504-6
Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., et al. (2009). Dystrophins carrying spectrin-like repeats 16/17 anchor nNOS to the sarcolemma and enhance exercise performance. J. Clin. Invest. 119, 624–635. doi: 10.1172/JCI36612
Lai, Y., Zhao, J., Yue, Y., and Duan, D. (2013). α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding. Proc. Natl. Acad. Sci. U.S.A. 110, 525–530. doi: 10.1073/pnas.1211431109
Li, D., Yue, Y., Lai, Y., Hakim, C. H., and Duan, D. (2011). Nitrosative stress elicited by nNOSmicro delocalization inhibits muscle force in dystrophin-null mice. J. Pathol. 223, 88–98. doi: 10.1002/path.2799
Marques, M. J., Luz, M. A., Minatel, E., and Neto, H. S. (2005). Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neurosci. Lett. 382, 342–345. doi: 10.1016/j.neulet.2005.03.023
Martin, E. A., Barresi, R., Byrne, B. J., Tsimerinov, E. I., Scott, B. L., Walker, A. E., et al. (2012). Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci. Transl. Med. 4, 162ra155. doi: 10.1126/scitranslmed.3004327
Mendell, J. R., Engel, W. K., and Derrer, E. C. (1971). Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science 172, 1143–1145. doi: 10.1126/science.172.3988.1143
Mendell, J. R., Engel, W. K., and Derrer, E. C. (1972). Increased plasma enzyme concentrations in rats with functional ischaemia of muscle provide a possible model of Duchenne muscular dystrophy. Nature 239, 522–524. doi: 10.1038/239522a0
Mizunoya, W., Upadhaya, R., Burczynski, F. J., Wang, G., and Anderson, J. E. (2011). Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm. Am. J. Physiol., Cell Physiol. 300, C1065–C1077. doi: 10.1152/ajpcell.00482.2010
Monaco, A. P., Neve, R. L., Colletti-Feener, C., Bertelson, C. J., Kurnit, D. M., and Kunkel, L. M. (1986). Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323, 646–650. doi: 10.1038/323646a0
Musch, B. C., Papapetropoulos, T. A., McQueen, D. A., Hudgson, P., and Weightman, D. (1975). A comparison of the structure of small blood vessels in normal, denervated and dystrophic human muscle. J. Neurol. Sci. 26, 221–234. doi: 10.1016/0022-510X(75)90034-9
Palladino, M., Gatto, I., Neri, V., Straino, S., Smith, R. C., Silver, M., et al. (2013). Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy. Arterioscler. Thromb. Vasc. Biol. 33, 2867–2876. doi: 10.1161/ATVBAHA.112.301172
Paulson, O. B., Engel, A. G., and Gomez, M. R. (1974). Muscle blood flow in Duchenne type muscular dystrophy, limb-girdle dystrophy, polymyositis, and in normal controls. J. Neurol. Neurosurg. Psychiatr. 37, 685–690. doi: 10.1136/jnnp.37.6.685
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., and Sweeney, H. L. (1993). Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U.S.A. 90, 3710–3714. doi: 10.1073/pnas.90.8.3710
Ravipati, G., McClung, J. A., Aronow, W. S., Peterson, S. J., and Frishman, W. H. (2007). Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol. Rev. 15, 76–86. doi: 10.1097/01.crd.0000233904.77128.49
Sander, M., Chavoshan, B., Harris, S. A., Iannoccone, S. T., Stull, J. T., Thomas, G. D., et al. (2000). Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 97, 13818–13823. doi: 10.1073/pnas.250379497
Sciorati, C., Miglietta, D., Buono, R., Pisa, V., Cattaneo, D., Azzoni, E., et al. (2011). A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol. Res. 64, 210–217. doi: 10.1016/j.phrs.2011.05.003
Singh, R. J., Hogg, N., Joseph, J., Konorev, E., and Kalyanaraman, B. (1999). The peroxynitrite generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors. Arch. Biochem. Biophys. 361, 331–339. doi: 10.1006/abbi.1998.1007
Straino, S., Germani, A., Di Carlo, A., Porcelli, D., De Mori, R., Mangoni, A., et al. (2004). Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation 110, 3341–3348. doi: 10.1161/01.CIR.0000147776.50787.74
Suzuki, N., Motohashi, N., Uezumi, A., Fukada, S., Yoshimura, T., Itoyama, Y., et al. (2007). NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J. Clin. Invest. 117, 2468–2476. doi: 10.1172/JCI30654
Thomas, G. D., Sander, M., Lau, K. S., Huang, P. L., Stull, J. T., and Victor, R. G. (1998). Impaired metabolic modulation of α-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 95, 15090–15095. doi: 10.1073/pnas.95.25.15090
Thomas, G. D., Shaul, P. W., Yuhanna, I. S., Froehner, S. C., and Adams, M. E. (2003). Vasomodulation by skeletal muscle-derived nitric oxide requires α-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ. Res. 92, 554–560. doi: 10.1161/01.RES.0000061570.83105.52
Thomas, G. D., and Victor, R. G. (1998). Nitric oxide mediates contraction-induced attenuation of sympathetic vasoconstriction in rat skeletal muscle. J. Physiol. 506, 817–826. doi: 10.1111/j.1469-7793.1998.817bv.x
Thomas, G. D., Ye, J., De Nardi, C., Monopoli, A., Ongini, E., and Victor, R. G. (2012). Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS ONE 7:e49350. doi: 10.1371/journal.pone.0049350
Tidball, J. G., and Wehling-Henricks, M. (2004). Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. Mol. Genet. Metab. 82, 312–320. doi: 10.1016/j.ymgme.2004.06.006
Torelli, S., Brown, S. C., Jimenez-Mallebrera, C., Feng, L., Muntoni, F., and Sewry, C. A. (2004). Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol. Appl. Neurobiol. 30, 540–545. doi: 10.1111/j.1365-2990.2004.00561.x
Voisin, V., Sebrie, C., Matecki, S., Yu, H., Gillet, B., Ramonatxo, M., et al. (2005). L-arginine improves dystrophic phenotype in mdx mice. Neurobiol. Dis. 20, 123–130. doi: 10.1016/j.nbd.2005.02.010
Wehling-Henricks, M., Jordan, M. C., Roos, K. P., Deng, B., and Tidball, J. G. (2005). Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum. Mol. Genet. 14, 1921–1933. doi: 10.1093/hmg/ddi197
Zhang, Y., Yue, Y., Li, L., Hakim, C. H., Zhang, K., Thomas, G. D., et al. (2013). Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum. Mol. Genet. 22, 3720–3729. doi: 10.1093/hmg/ddt224
Keywords: Duchenne muscular dystrophy, neuronal nitric oxide synthase, exercise, functional sympatholysis, sympathetic vasoconstriction
Citation: Thomas GD (2013) Functional muscle ischemia in Duchenne and Becker muscular dystrophy. Front. Physiol. 4:381. doi: 10.3389/fphys.2013.00381
Received: 23 September 2013; Accepted: 04 December 2013;
Published online: 18 December 2013.
Edited by:Mark Chapleau, University of Iowa, USA
Reviewed by:Scott A. Smith, University of Texas Southwestern Medical Center at Dallas, USA
Stephen E. DiCarlo, Wayne State University, USA
Harald M. Stauss, The University of Iowa, USA
Copyright © 2013 Thomas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gail D. Thomas, Heart and Vascular Institute, Penn State College of Medicine, 500 University Drive, H047, Hershey, PA 17033, USA e-mail: email@example.com